W
WAVEMAN · COMPANY
LTRN · Lantern Pharma Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

LTRN

Lantern Pharma Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001763950
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$200.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
20
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$200.0K over 180 days
more than 80% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
20 funds added or opened last quarter
below 69% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
6.6% of shares outstanding short · 10.1 days to cover · settled 2026-07-31
more than 63% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -52.7%
-52.7%12M
-72%-43%-14%+15%2025-092025-102025-122026-032026-052026-072026-09 2026-05-12 · Schalop Lee Troy bought $100.0K2026-05-12 · KEYSER D JEFFREY bought $100.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $200.0K bought by insiders over 180 days, 20 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Lantern Pharma Inc. insiders bought a net $200.0K of stock across 124 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Schalop Lee Troy
Director
BUY
2026-05-12
48,544.0
$100.0K
KEYSER D JEFFREY
Director
BUY
2026-05-12
48,544.0
$100.0K
BIOS Fund II QP, LP
SELL
2025-06-13
12,319.0
$38.1K
BIOS Fund II QP, LP
SELL
2025-06-13
4,354.0
$13.5K
BIOS Fund II QP, LP
SELL
2025-06-13
1,903.0
$5.9K
124 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 119 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Empery Asset Management, LP
842,669.0 sh
$3.5M
CM Management, LLC
500,000.0 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
425,118.0 sh
$1.8M
RENAISSANCE TECHNOLOGIES LLC
291,039.0 sh
$1.2M
BIOS Capital Management, LP
249,397.0 sh
$1.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Horizon Kinetics Medical ETF
$36.1K POSITION · AS OF 2026-03-31
0.2%
iShares Micro-Cap ETF
$29.3K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$2.3K POSITION · AS OF 2026-03-31
0.0%
U.S. Social Core Equity 2 Portfolio
$19.9K POSITION · AS OF 2026-04-30
0.0%
Fidelity Extended Market Index Fund
$129.4K POSITION · AS OF 2026-02-28
0.0%
Dimensional US Sustainability Core 1 ETF
$3.9K POSITION · AS OF 2026-04-30
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
1
Phase 2
1 ACTIVE
1
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-18.0M$-22.2M$-17.9M$-14.4M
NET INCOME$-17.1M$-20.8M$-16.0M$-14.3M
EPS (DILUTED)-1.57-1.93-1.47-1.31
OPERATING CASH FLOW$-15.7M$-17.8M$-14.3M$-12.8M
CASH$4.4M$7.5M$21.9M$37.2M
BUYBACKS$500.0K$2.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →